Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation

Journal of Geriatric Cardiology

Volumn 13, Issue 7, 2016, Pages 559-565

  Jankowska Polańska, Beata ^a   Katarzyna, Lomper ^a   Lidia, Alberska ^b   Joanna, Jaroch ^b   Dudek, Krzysztof ^c   Izabella, Uchmanowicz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Department of Neurosurgery   (Poland)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Anticoagulation treatment; Atrial fibrillation; Cognitive impairment; Medication adherence

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

8 ITEM MORISKY MEDICATION ADHERENCE SCALE; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; COGNITIVE DEFECT; CORRELATION COEFFICIENT; DEMENTIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; PATIENT COMPLIANCE; RATING SCALE; SCORING SYSTEM; VERY ELDERLY;

EID: 84981170298     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.11909/j.issn.1671-5411.2016.07.006     Document Type: Article

References (34)

1. Zoni-Berisso M, Lercali F, Carazza L, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213-220.
2. Mahtani KR, Heneghan CJ, Nunan D, et al. Vitamin K for improved anticoagulation control in patients receiving warfarin. Cochrane Database Syst Rev 2014; CD009917.
3. Mahtani K, Heneghan C, Glasziou P, et al. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev 2011; 9: 1-62.
4. Ferguson C, Inglis SC, Newton PJ, et al. The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review. Eur J Cardiovasc Nurs 2015; 14: 98-107.
5. Laliberté F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012; 29: 675-690.
6. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010; 3: 624-631.
7. Precioso Costa FJ, Larré Muñoz MJ, Navarro Ros FM, et al. [Level of control and treatment adherence of anticoagulation with acenocoumarol in primary care]. Semergen 2015; S1138-3593(15)00304-4. [Article in Spanish].
8. Gumbinger C, Holstein T, Stock C, et al. Reasons underlying nonadherence and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. Eur Neurol 2015; 73: 184-191.
9. Heidbuchel H, Verhamme P, Alings P, et al. Updated European Heart Rhythm Association Practical Guide on the use the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507.
10. Zeolla MM, Brodeur RR, Dominelli A, et al. Development and validation of an instrument to determine patient knowledge: the oral anticoagulation knowledge test. Ann Pharmacother 2006; 40: 633-638.
11. Briggs AL, Jackson TR, Bruce S, et al. The development and performance validation of a tool to assess patient anticoagulation knowledge. Res Social Adm Pharm 2005; 1: 40-59.
12. Van Damme S, Van Deyk K, Moons P, et al. Instruments to assess patient's knowledge regarding oral anticoagulation therapy: a systematic review. Eur J Cardiovasc Nurs 2008; 7: 21-22.
13. Avila ChW, Aliti GB, Feijo MKF, et al. Pharmacological adherence to oral anticoagulant and factors that influence the international normalized ratio stability. Rev Latino-Am. Enfermagem 2011; 19: 18-25.
14. Marzona I, O'Donell M, Koon T, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ 2012; 184: E329-E336.
15. Campbell NL, Boustani MA, Skopelja EN, et al. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother 2012; 10: 165-177.
16. Horstmann S, Rizos T, Saribas M, et al. Cognitive impairment is not a predictor of failure to adhere to anticoagulation of stroke patients with atrial fibrillation. Cerebrovasc Dis 2015; 39: 325-331.
17. Castellucci LA, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res 2015; 136: 727-731.
18. Mayet AY. Patient adherence to warfarin therapy and its impact on anticoagulation. Saudi Pharm J 2016; 24; 29-34.
19. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
20. Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008; 10: 348-354.
21. Crum RM, Anthony JC, Bassett SS, et al. Population-based norms for the mini-mental state examination by age and educational level. J Am Med Assoc 1993; 269: 2386-2391.
22. Dublin S, Anderson ML, Haneuse SJ, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc 2011; 59: 1369-1375.
23. Flaker GC, Pogue J, Yusuf S, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010; 3: 277-283.
24. Annweiler C, Ferland G, Barberger-Gateau P, et al. Vitamin K antagonists and cognitive impairment: results from a cross-sectional pilot study among geriatric patients. J Gerontol A Biol Sci Med Sci 2015; 70: 97-101.
25. Wang Y, Kong MC, Lee LH, et al. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 2014; 133: 550-554.
26. van Deelen BA, van den Bemt PM, Egberts TC, et al. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging 2005; 22: 353-360.
27. Arlt S, Lindner R, Rosler A, et al. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging 2008; 25: 1033-1047.
28. Insel K, Morrow D, Brewer B, et al. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci 2006; 61: P102-P107.
29. Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol 2001; 57: 589-594.
30. Rauch G, Veltkamp R. Cognitive impairment is not a predictor of failure to adhere to anticoagulation of stroke patients with atrial fibrillation. Cerebrovasc Dis 2015; 39: 325-331.
31. Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother 2001; 35: 539-545.
32. Salas M, In't Veld BA, van der Linden PD, et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study. Clin Pharmacol Ther 2001; 70: 561-566.
33. Barat I, Andreasen F, Damsagaard EMS. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol 2001; 51: 615-622.
34. Perera V, Bajorek BV, Matthews S, et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009; 38: 156-162.